Dialysis-related carnitine disorder

Seminars in Dialysis

Volumn 19, Issue 4, 2006, Pages 323-328

  Susan Hedayati, S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE;

ANEMIA; CHRONIC KIDNEY FAILURE; HUMAN; KIDNEY; METABOLISM; MUSCLE DISEASE; RENAL REPLACEMENT THERAPY; REVIEW;

ANEMIA; CARNITINE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MUSCULAR DISEASES; RENAL DIALYSIS;

EID: 33746237574     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00180.x     Document Type: Review

References (71)

1. Bremer J: Carnitine - metabolism and functions. Physiol Rev 63:1420-1480, 1983
2. Rebouche CJ, Paulson DJ: Carnitine metabolism and function in humans. Ann Rev Nutr 6:41-66, 1986
3. Rebouche CJ, Seim H: Carnitine metabolism and its regulation in microorganisms and mammals. Ann Rev Nutr 18:39-61, 1998
4. Evans A: Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis 41(suppl 4):S13-S26, 2003
5. Ramsey RR, Gandour RD, van der Leij FR: Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta 1546:21-43, 2001
6. Savica V, Calvani M, Benatti P, Santoro D, Monardo P, Peluso G, Bellinghieri G: Carnitine system in uremic patients: molecular and clinical aspects. Semin Nephrol 24:464-468, 2004
7. Hoppel C: The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis 41(suppl 4):S4-S12, 2003
8. Parvin R, Pande SV: Enhancement of mitochondrial carnitine and carnitine acylcarnitine translocase-mediated transport of fatty acids into liver mitochondria under ketotic conditions. J Biol Chern 254:5423-5429, 1979
9. Ramsay RR, Gandour RD: Selective modulation of carnitine long-chain acyltransferase activities. Kinetics, inhibitors, and active sites of COT and CPT-II. Adv Exp Med Biol 466:103-109, 1999
10. Lysiak W, Toth PP, Suelter CH, Bieber LL: Quantitation of the efflux of acylcarnitines from rat heart, brain, and liver mitochondria. J Biol Chem 261:13698-13703, 1986
11. Lysiak W, Lilly K, Di Lisa F, Toth PP, Bieber LL: Quantitation of the effect of L-carnitine on the levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. J Biol Chem 263:1151-1156, 1988
12. Hokland BM: Uptake, metabolism and release of carnitine and acylcarnitines in the perfused rat liver. Biochim Biophys Acta 961:234-241, 1988
13. Kerner J, Bieber LL: Isolation and identification of alpha- methyloctanylcarnitines from human urine. Prep Biochem 15:237-257, 1985
14. Buechler KF, Lowenstein JM: The involvement of carnitine intermediates in peroxisomal fatty acid oxidation: a study with 2-bromofatty acids. Arch Biochem Biophys 281:233-238, 1990
15. Branca D, Di Lisa F, Scutari G, Toninello A, Siliprandi N: Stabilizing action of L-carnitine on energy-linked processes of mitochondria isolated from perfused rat liver. Biochem Pharmacol 35:2839-2841, 1986
16. Lombard KA, Olson A, Nelson SE, Rebouche CJ: Carnitine status of lactoovovegetarians and strict vegetarian adults and children. Am J Clin Nutr 50:301-306, 1989
17. Rebouche CJ: Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism 40:1305-1310, 1991
18. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A: Molecular and functional identification of sodium ion-dependent, high-affinity human carnitine transporter OCTN2. J Biol Chem 273:20378-20382, 1998
19. Wang Y, Ye J, Ganpathy V, Longo N: Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc Natl Acad Sci USA 96:2356-2360, 1999
20. Harper P, Elwin C, Cederblad G: Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. Eur J Clin Pharmacol 35:69-75, 1988
21. Pace S, Longo A, Toon S, Rolan P, Evans AM: Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. Br J Clin Pharmacol 50:441-448, 2000
22. Hokland BM, Bremer J: Metabolism and excretion of carnitine and acylcarnitines in the perfused rat kidney. Biochim Biophys Acta 886:223-230, 1986
23. Rebouche CJ, Lombard KA, Chenard CA: Renal adaptation to dietary carnitine in humans. Am J Clin Nutr 58:660-665, 1993
24. Evans AM, Mancinelli A, Longo A: Excretion and metabolism of propionyl-L-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther 281:1071-1076, 1997
25. Mancinelli A, Longo A, Shanahan K, Evans AM: Disposition of L-carnitine and acetyl-L-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther 274:1122-1128, 1997
26. Evans AM, Faull RJ, Nation RL, Prasad S, Elias T, Reuter SE, Fornasini G: Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease. Kidney Int 66:1527-1534, 2004
27. Bartel LL, Hussey JL, Shrago E: Perturbation of serum carnitine levels in human adults by chronic renal disease and dialysis therapy. Am J Clin Nutr 34:1314-1320, 1981
28. Sakurauchi Y, Matsumoto Y, Shinzato T, Takai I, Nakamura Y, Sato M, Nakai S, Miwa M, Morita H, Miwa T, Amano I, Maeda K: Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients. Am J Kidney Dis 32:258-264, 1998
29. Debska-Slizien A, Kawecka A, Wojnarowski K, Prajs J, Malgorzewicz S, Kunicka D, Zdrojewski Z, Walysiak S, Lipinski J, Rutkowski B: Correlation between plasma carnitine, muscle carnitine and glycogen levels in maintenance hemodialysis patients. Int J Artif Organs 23:90-96, 2000
30. Ahmad S: L-carnitine in dialysis patients. Semin Dial 14:209-217, 2001
31. Evans AM, Faull R, Fornasini G, Lemanowicz EF, Longo A, Pace S, Nation RL: Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Clin Pharmacol Ther 68:238-249, 2000
32. Hiatt WR, Koziol BJ, Shapiro JI, Brass EP: Carnitine metabolism during exercise in patients on chronic hemodialysis. Kidney Int 41:1613-1619, 1992
33. Bellinghieri G, Savica V, Mallamace A, Di Stefano C, Consolo F, Spagnoli LG, Villaschi S, Palmieri G, Corsi M, Maccari F: Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 38:523-531, 1983
34. Savica V, Bellinghieri G, Di Stefano C, Corvaja E, Consolo F, Corsi M, Maccari F, Spagnoli LG, Villaschi S, Palmieri G: Plasma and muscle carnitine levels in haemodialysis patients with morphological-ultrastructural examination of muscle samples. Nephron 35:232-236, 1983
35. Rebouche CJ, Engel AG: Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport. J Clin Invest 73:857-867, 1984
36. Spagnoli LG, Palmieri G, Mauriello A, Vacha GM, D'Iddio S, Giorcelli G, Corsi M: Morphometric evidence of the trophic effect of L-carnitine on human skeletal muscle. Nephron 55:16-23, 1990
37. Casciani CU, Caruso U, Cravotto E: Beneficial effects of L-carnitine in post dialysis syndrome. Curr Ther Res Clin Exp 32:116-127, 1982
38. Ahmad S, Robertson HT, Golper TA, Wolfson M, Kurtin P, Katz LA, Hirschberg R, Nicora R, Ashbrook DW, Kopple JD: Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 38:912-918, 1990
39. Fagher B, Cederblad G, Eriksson M, Monti M, Moritz U, Nilsson-Ehle P, Thysell H: L-carnitine and hemodialysis: double blind study on muscle function and metabolism and peripheral nerve function. Scand J Clin Lab Invest 45:169-178, 1985
40. Mioli V, Tarchini R, Boggi R: Use of D,L- and L-carnitine in uremic patients on intermittent haemodialysis. Int J Clin Pharmacol Res 2:143-148, 1982
41. Albertazzi A, Spisni C, Del Rosso G, Palmieri PF, Rossini PM: Electromyographic changes induced by oral carnitine treatment in dialysis patients. Proc Clin Dial Transplant Forum 10:1-6, 1980
42. Siami G, Clinton ME, Mrak R, Griffis J, Stone W: Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron 57:306-313, 1991
43. Golper TA, Goral S, Becker BN, Langman CB: L-carnitine treatment of anemia. Am J Kidney Dis 41(suppl 4):S27-S34, 2003
44. Matsumura M, Hatakeyamma S, Koni I, Mabuchi H, Muramoto H: Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron 72:574-578, 1996
45. Nikolaos S, George A, Telemachos T, Maria S, Yannis M, Konstantinos M: Effect of L-carnitine supplementation on red blood cell deformability in hemodialysis patients. Ren Fail 22:73-80, 2000
46. Berard E, Barrillon D, Iordache A, Bayle J, Cassuto-Viguier E: Low dose of L-carnitine improves membrane fragility of erythrocytes in hemodialysis patients [letter]. Nephron 68:145, 1994
47. Labonia WD, Morelli OH Jr, Gimenez MI, Freuler PV, Morelli OH: Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients. Kidney Int 32:754-759, 1987
48. Trovato GM, Ginardi V, Di Marco V, Dell'Aira AE, Corsi M: Long term L-carnitine treatment of chronic anaemia of patients with end stage renal failure. Curr Ther Res 31:1042-1049, 1982
49. Nilsson-Ehle P, Cederblad G, Fagher B, Monti M, Thysell H: Plasma lipoproteins, liver function and glucose metabolism in haemodialysis patients: lack of effect of L-carnitine supplementation. Scand J Clin Lab Invest 45:179-184, 1985
50. Labonia WD: L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 26:757-764, 1995
51. Caruso U, Leone L, Cravotto E, Nava D: Effects of L-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin: a pilot study. Dial Transplant 27:498-506, 1998
52. Albertazzi A, Capelli P, Di Paolo B, Pola P, Tondi P, Vaccario O: Endocrine-metabolic effects of L-carnitine in patients on regular dialysis treatment. Proc Eur Dial Transplant Assoc 19:302-307, 1983
53. van Es A, Henny FC, Kooistra MP, Lobatto S, Scholte HR: Amelioration of cardiac function by L-carnitine administration in patients on hemodialysis. Contrib Nephrol 98:28-35, 1992
54. Fagher B, Cederblad G, Monti M, Olsson L, Rasmussen B, Thysell H: Carnitine and left ventricular function in hemodialysis patients. Scand J Clin Lab Invest 45:193-198, 1985
55. Golper TA, Wolfson M, Ahmad S, Hirschberg R, Kurtin P, Katz LA, Nicora R, Ashbrook D, Kopple JD: Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentration and lipid effects. Kidney Int 38:904-911, 1990
56. Yderstraede KB, Pedersen FB, Dragsholt C, Trostmann A, Laier E, Larsen HF: The effect of L-carnitine on lipid metabolism in patients on chronic hemodialysis. Nephrol Dial Transplant 1:238-241, 1987
57. Weschler A, Aviram M, Levin M, Better OS, Brook JG: High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis. Nephron 38:120-124, 1984
58. Guarnieri GF, Ranieri F, Toigo G, Vasile A, Ciman M, Rizzoli V, Moracchiello M, Campanacci L: Lipid-lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis. Am J Clin Nutr 33:1489-1492, 1980
59. Hurot JM, Cucherat M, Haugh M, Fougue D: Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 13:708-714, 2002
60. Wanner C, Wieland H, Wackerle B, Boeckle H, Schollmeyer P, Horl WH: Ketogenic and antiketogenic effects of L-carnitine in hemodialysis patients. Kidney Int Suppl 27:S264-S268, 1989
61. Elisaf M, Bairaktari E, Katopodis K, Pappas M, Sferopoulos G, Tzallas C, Tsolas O, Siamopoulos KC: Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients. Am J Nephrol 18:416-421, 1998
62. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM: Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 55:1945-1951, 1999
63. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, Uretsky B, Smiley M, Gold J, Muniz H, Badalamenti J, Herzog C, Henrich W: Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 290:353-359, 2003
64. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, Sanderson JE: Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 15:2186-2194, 2004
65. Bellinghieri G, Santoro D, Calvani M, Savica V: Role of carnitine in modulating acute-phase protein synthesis in hemodialysis patients. J Ren Nutr 15:13-17, 2005
66. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 54:236-244, 1998
67. Bistrian BR, Schwartz J, Istfan NW: Cytokines, muscle proteolysis, and the catabolic response to infection and inflammation. Proc Soc Exp Biol Med 200:220-223, 1992
68. Grazi G, Meriggioli M, Donati G: [Can the treatment with L-carnitine improve the inflammation in chronic hemodialysis patients?]. G Ital Nefrol 21(suppl 30):S204-S207, 2004
69. Sohn HJ, Choi GB, Yoon KI: [L-carnitine in maintenance hemodialysis clinical, lipid and biochemical effects]. Kor J Nephrol 11:260, 1992
70. Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A: Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 37:1018-1028, 2001
71. Sloan RS, Kastan B, Rice SI, Sallee CW, Yuenger NJ, Smith B, Ward RA, Brier ME, Golper TA: Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation. Am J Kidney Dis 32:265-272, 1998